Haney Margaret, Bisaga Adam, Foltin Richard W
New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Drive, Unit 120, New York, NY 10032, USA.
Psychopharmacology (Berl). 2003 Feb;166(1):77-85. doi: 10.1007/s00213-002-1279-8. Epub 2002 Dec 19.
Studies in non-human animals suggest that opioid antagonists block the reinforcing effects of cannabinoids.
The present studies in humans investigated how naltrexone modulates (1) the subjective and physiological effects of oral THC in comparison to methadone, (2) the reinforcing effects of oral THC, and (3) plasma levels of oral THC.
In study 1, marijuana smokers (n=9) received naltrexone (0, 50 mg) followed 30 min later by THC (0, 15, 30 mg) or methadone (5, 10 mg). Subjective effects, task performance, pupillary diameter, and cardiovascular parameters were measured repeatedly. In study 2a, marijuana smokers (n=23) were randomly assigned to one THC dose condition (0, 15 or 30 mg). One set of color-coded capsules containing THC and active naltrexone (50 mg) was given in one session, while another set of color-coded capsules containing THC and placebo naltrexone was given in another session. In the final three sessions, participants chose which color capsules they would receive. In study 2b, a subset of participants from study 2a (n=7) received naltrexone (0, 50 mg) 30 min prior to oral THC (30 mg) administration, and blood was drawn repeatedly.
Pretreatment with naltrexone significantly increased many of the "positive" subjective effects of oral THC (30 mg) e.g. ratings of Good Drug Effect and Capsule Liking. Naltrexone tended to increase the reinforcing effects of oral THC (30 mg), as indicated by performance in a drug choice test. Naltrexone did not alter plasma THC levels.
These studies demonstrate that naltrexone increases the subjective effects of oral THC. Thus, oral THC's effects are enhanced rather than antagonized by opioid receptor blockade in heavy marijuana smokers.
对非人类动物的研究表明,阿片类拮抗剂可阻断大麻素的强化作用。
目前针对人类的研究调查了纳曲酮如何调节:(1)与美沙酮相比,口服四氢大麻酚(THC)的主观和生理效应;(2)口服THC的强化作用;(3)口服THC的血浆水平。
在研究1中,大麻吸食者(n = 9)先服用纳曲酮(0、50毫克),30分钟后再服用THC(0、15、30毫克)或美沙酮(5、10毫克)。重复测量主观效应、任务表现、瞳孔直径和心血管参数。在研究2a中,大麻吸食者(n = 23)被随机分配到一种THC剂量条件(0、15或30毫克)。在一个疗程中给予一组含有THC和活性纳曲酮(50毫克)的颜色编码胶囊,而在另一个疗程中给予另一组含有THC和安慰剂纳曲酮的颜色编码胶囊。在最后三个疗程中,参与者选择他们将接受哪种颜色的胶囊。在研究2b中,来自研究2a的一部分参与者(n = 7)在口服THC(30毫克)前30分钟服用纳曲酮(0、50毫克),并多次采血。
用纳曲酮预处理显著增加了口服THC(30毫克)的许多“积极”主观效应,例如对良好药物效果和胶囊喜好的评分。如在药物选择测试中的表现所示,纳曲酮倾向于增加口服THC(30毫克)的强化作用。纳曲酮未改变血浆THC水平。
这些研究表明,纳曲酮增加了口服THC的主观效应。因此,在重度大麻吸食者中,口服THC的效应通过阿片受体阻断得到增强而非拮抗。